Michael Ulz
Stock Analyst at Morgan Stanley
(3.54)
# 727
Out of 4,814 analysts
117
Total ratings
42.37%
Success rate
6.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $284 → $268 | $234.75 | +14.16% | 10 | Apr 11, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $1.85 | +984.01% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.11 | +1,881.98% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $6.92 | +319.08% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $4.69 | +49.25% | 7 | Mar 5, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $49 → $45 | $3.15 | +1,328.57% | 11 | Mar 5, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $75 → $54 | $5.06 | +968.25% | 5 | Mar 3, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $3.07 | +551.47% | 4 | Feb 28, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Equal-Weight | $20 → $5 | $5.15 | -2.82% | 5 | Feb 12, 2025 | |
| GUTS Fractyl Health | Maintains: Overweight | $18 → $10 | $1.22 | +719.67% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $37.65 | +155.01% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $23.83 | +340.62% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $8.18 | +536.09% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $115 | $84.69 | +35.79% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $38.63 | +47.55% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $11.21 | +140.86% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.12 | +525.00% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $28.32 | +69.49% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $4.77 | +466.63% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $3.83 | +422.88% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.33 | +610.90% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.75 | +1,234.22% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $0.33 | +2,351.73% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $1.25 | +140.00% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.47 | +448.95% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.24 | +2,329.15% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $6.45 | +597.67% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.35 | +5,540.16% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $35.64 | +124.47% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $6.83 | +119.78% | 3 | Jul 12, 2017 |
Alnylam Pharmaceuticals
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $284 → $268
Current: $234.75
Upside: +14.16%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $1.85
Upside: +984.01%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.11
Upside: +1,881.98%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $6.92
Upside: +319.08%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $4.69
Upside: +49.25%
Silence Therapeutics
Mar 5, 2025
Maintains: Overweight
Price Target: $49 → $45
Current: $3.15
Upside: +1,328.57%
Karyopharm Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $75 → $54
Current: $5.06
Upside: +968.25%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.07
Upside: +551.47%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20 → $5
Current: $5.15
Upside: -2.82%
Fractyl Health
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.22
Upside: +719.67%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $37.65
Upside: +155.01%
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $23.83
Upside: +340.62%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $8.18
Upside: +536.09%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $84.69
Upside: +35.79%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $38.63
Upside: +47.55%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $11.21
Upside: +140.86%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.12
Upside: +525.00%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $28.32
Upside: +69.49%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $4.77
Upside: +466.63%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $3.83
Upside: +422.88%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $6.33
Upside: +610.90%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.75
Upside: +1,234.22%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.33
Upside: +2,351.73%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $1.25
Upside: +140.00%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.47
Upside: +448.95%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.24
Upside: +2,329.15%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $6.45
Upside: +597.67%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.35
Upside: +5,540.16%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $35.64
Upside: +124.47%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $6.83
Upside: +119.78%